Intra-operative Detection of Positive Margins in Breast Surgery

NCT ID: NCT06977698

Last Updated: 2025-05-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-10-01

Study Completion Date

2027-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this project, we will develop a unique OCT-Raman system based on a selective sampling approach optimised for high-resolution analysis of whole lumpectomy specimens. The aim of using OCT is not to detect the cancer but to identify the adipose tissue, such that the large adipose tissue regions are excluded from any further measurements by Raman spectroscopy.

While OCT has a limited ability to distinguish between tumour and surrounding normal stroma, adipose tissue has a distinctive appearance in the OCT images due to low backscattering within adipose cells (filled with lipids and small/flattened nuclei) compared to the highly scattering benign dense tissue (stroma, ducts and lobules) and malignant tissue. Such specific patterns allow identification of normal adipose tissue from breast tissue (classification models based on reflectivity profiles) with 94% sensitivity and 93% specificity. This will reduce the task of Raman measurements, which can be focused on the smaller remaining regions to discriminate between the benign and malignant tissue. This flexible and adaptable scanning strategy will achieve a much-improved diagnosis accuracy and speed to cover all surgical margins within practical timescales.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The new OCT-Raman system developed in this project will integrate both modules into a single instrument and rely on deep learning algorithms to automatically acquire and analyse data. The OCT module will be designed for fast scanning large lumpectomy specimens (include focus adjustment for irregular 3D surfaces) and machine learning (ML) algorithms will identify the regions of interest (non-adipose tissue" in the OCT images, automatically directing the Raman spectroscopy measurements to these "high-risk areas". A second layer of machine learning models will then classify the Raman spectra to discriminate the cancer (positive margins) from benign tissue. This approach simplifies the use of the instrument, reduces subjectivity and user training: the user will be required only to insert the tissue in the instrument, all steps being afterwards automated (OCT and Raman measurements and analysis) until the display of the final diagnosis map showing any positive margins in red colour. The unique OCT-Raman system will translate the high diagnosis accuracy of Raman spectroscopy from mm-scale to whole lumpectomy level, providing a tool for surgeons to identify positive margins intra-operatively. The Uon team has demonstrated this concept in an instrument based on AF and Raman spectroscopy for the detection of positive margins during Mohs micrographic surgery for skin cancers. The OCT-Raman device that will be used in this study has been developed by the University of Nottingham. This is a proof-of-concept study of a device developed in-house, being undertaken at a single centre only, and the results generated from using the device will not be used to direct or influence the participant's clinical care.

When the machine is already calibrated and trained to differentiate between tumour and normal tissue, we will scan the surface of the wide local excision specimen without handling of the tissue, and return it to the pathologist for routine processing. The tissue slice will not be used for any research purposes. Any identifiable information will only be accessed by members of the clinical care team, and the samples will remain anonymous to the researchers who are not members of the clinical care team.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Invasive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

OCT-Raman

a machine to detect positive margins in lumpectomy specimens

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients undergoing breast surgery (wide local excision).
* Able to give informed consent.
* Any age.

Exclusion Criteria

• Patients where there is any doubt regarding the diagnosis from pathologist as ascertained by previous diagnostic biopsy.
Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Nottingham

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ioan Notingher

Role: PRINCIPAL_INVESTIGATOR

University of Nottingham

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Nottingham university hospitals

Nottingham, , United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ioan Notingher

Role: CONTACT

0)115 951 3082 ext. 951 5374

Nehal Atallah

Role: CONTACT

07521100084

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Nehal Atallah, PhD

Role: primary

07521100084

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

336788

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Using Diagnostic Tools to Stage Breast Cancer
NCT00367666 ACTIVE_NOT_RECRUITING NA